110PImmune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?. (23rd October 2018) - Matos Garcia, I; Azaro, A; Viaplana, C; Hierro, C; Martin-Liberal, J; Brana, I; Gardeazabal, I; Gomila, P; Vieito Villar, M; Ochoa De Olza Amat, M; Elez Fernandez, E; Oliveira, M; et al.